z-logo
open-access-imgOpen Access
Eligibility for and Prescription of Urate-Lowering Treatment in Patients With Incident Gout in England
Author(s) -
ChangFu Kuo,
Matthew J. Grainge,
Christian Mallen,
Weiya Zhang,
Michael Doherty
Publication year - 2014
Publication title -
jama
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 4.688
H-Index - 680
eISSN - 1538-3598
pISSN - 0098-7484
DOI - 10.1001/jama.2014.14484
Subject(s) - gout , medicine , hyperuricemia , medical prescription , concomitant , uric acid , intensive care medicine , pharmacology
Gout is caused by urate crystal deposition secondary to persistent hyperuricemia. Current guidelines recommend urate-lowering treatment to prevent crystal deposition and encourage crystal dissolution for patients with more severe gout or concomitant conditions.1,2 However, after the first diagnosis, it remains unclear when such treatment is appropriate. We investigated the timing of eligibility for and prescription of urate-lowering treatment following first gout diagnosis and factors associated with prescription

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here
Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom